Aurobindo Pharma’s CuraTeQ Biologics completes Phase 1 study of bone drug

Aurobindo Pharma’s CuraTeQ Biologics reported successful trial results for BP16, a bone treatment drug. BP16 showed bioequivalence to Prolia in trials with 204 volunteers.

Leave a Reply

Your email address will not be published. Required fields are marked *